Notifications
Clear all
Weight Loss Centered
0
Posts
1
Users
0
Reactions
0
Views
0
03/10/2026 3:43 pm
Topic starter
Translate
â–¼
English
Spanish
French
German
Italian
Portuguese
Russian
Chinese
Japanese
Korean
Arabic
Hindi
Dutch
Polish
Turkish
Vietnamese
Thai
Swedish
Danish
Finnish
Norwegian
Czech
Hungarian
Romanian
Greek
Hebrew
Indonesian
Malay
Ukrainian
Bulgarian
Croatian
Slovak
Slovenian
Serbian
Lithuanian
Latvian
Estonian
The modern weight-management revolution has largely been driven by one hormone pathway: GLP-1. Semaglutide demonstrated how dramatically GLP-1 receptor activation could affect appetite, body weight and metabolic health. Tirzepatide then expanded the concept by simultaneously targeting GIP and GLP-1 receptors. Retatrutide is pushing the science further by investigating combined GIP, GLP-1 and glucagon receptor activation. But another approach is rapidly emerging. Instead of adding GIP or glucagon to GLP-1, researchers are increasingly interested in combining GLP-1 with another powerful satiety hormone: Amylin. One of the most exciting compounds emerging from this field is amycretin, now formally known as zenagamtide. Developed by…
Peptide Forum Disclaimer: The Peptide-Gold.com peptide forum is an open peptide community created for educational discussion, research information, and the exchange of knowledge about peptides. Posts, comments, opinions, recommendations, links, and other content shared within the peptide forum are created by individual users and do not necessarily represent the views of Peptide-Gold.com. Peptide-Gold.com does not endorse, verify, or accept responsibility or liability for content posted by members of the peptide community, its accuracy, or any actions taken based upon that information. All information shared within the peptide forum is for general educational and informational purposes only and should not be considered medical advice, diagnosis, treatment, or a recommendation for human use.